Format

Send to

Choose Destination
Bull Cancer. 2007 Oct;94(10):863-9.

[Treatment of chronic myeloid leukemia in 2007].

[Article in French]

Author information

1
Hématologie clinique, Pavillon E, Hôpital Edouard-Herriot, 5, place d'Arsonval, 69437 Lyon.

Abstract

The treatment of chronic myeloid leukemia (CML) has considerably evolved since imatinib mesylate has been introduced as a new therapeutic weapon for this disease. The 5-year updated results of the IRIS study confirmed that imatinib mesylate is the best first line therapy for chronic phase CML with an overall survival of 90%. Responses improve with time and complete cytogenetic and major molecular levels reach 87 and 70% respectively at 5 years. However, despite these remarkable improvements, new problems arise as sub-optimal responses, imatinib-resistances with recently identified BCR-ABL protein point mutations, responsible for a variety of therapeutic consequences : imatinib dose increase, alternative treatments with second generation tyrosine kinase inhibitors (TKIs : dastinib, nilotinib) or allogeneic stem cell transplantation. The treatment of accelerated and blastic phases relies on imatinib +/- conventional chemotherapy, ideally followed by allogeneic stem cell transplantation, as newly developed TKIs are currently evaluated within this frame. Finally, BCR-ABL(T315I) mutations remain a new therapeutic critical challenge as none of the three TKIs (imatinib, nilotinib, dasatinib) can efficiently control such diseases.

PMID:
17964980
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for John Libbey Eurotext
Loading ...
Support Center